Skip to main content

Industry News

academics

 

Clinical research courses

  • Johnson & Johnson will stop selling 128 years old Talc-based baby powder

    Johnson & Johnson has announced that it will discontinue talc-based baby powder worldwide after two years of withdrawing sell of talc-based baby powder in the United States and Canada. The company will stop selling the product in the global market from 2023.

  • FDA found cancer causing impurity in anti-diabetic medicine

    FDA found out cancer causing impurity in commonly used anti-diabetic medicines,  sitagliptin and notified in Drug safety report. FDA recently became aware of a nitrosamine impurity, Nitroso-STG-19 (known as NTTP), in certain samples of sitagliptin, a medicine used to treat type 2 diabetes mellitus.

  • Zydus receives final approval from the USFDA for Prochlorperazine Maleate Tablets

    Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to market Prochlorperazine Maleate tablets, USP 5 mg and 10 mg.

    Prochlorperazine tablets are used to treat nervous, emotional, and mental conditions (eg. schizophrenia) and non-psychotic anxiety. It is also used to control severe nausea and vomiting. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.

  • Kumar Organic Products Limited starts APPLIED LAB In Singapore

    Applied Lab has been started by Kumar Organic Singapore Pte. Ltd. in Singapore at Science Park Road, #04-07C, The Gemini, Lobby B, by inaugurating it on 4th August 2022.

    Guest of Honor during inaugural was Indian High Commissioner Mr.P.Kumaran. Lightening of candle was done by Mr. EngHeng Khoo, VP of Clariant South East Asia Pte. Ltd. 

  • Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations

    Nevro Corp and Boston Scientific Corp announced today that they have reached a settlement in their ongoing intellectual property litigations that gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, and gives Nevro the freedom to operate using the features and capabilities embodied in its current line of products.

  • NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution

    Natco Pharma Limitedannounces that the U.S. Food and Drug Administration has granted approval to its partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) for the 60mg/1.5mL (40mg/mL) strength.

  • Cosmohome Tech Expo 2022

    Cosmohome Tech Expo was held in Delhi at Pragati Maidan on 14th & 15th July 2022. Cosmohome Tech Expo is South Asia’s largest manufacturing trade show for the Cosmetic, Personal care, Cosmeceutical, Perfumery & Soap, detergent, and toiletries market. It is conceptualized on bringing the complete Innovative solutions to the beauty manufacturers right from the concept to formulation to technology to product launch for making the advancements in the manufacturing world.

  • Dr. Reddys Laboratories announces the launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. market

    Dr. Reddys Laboratories Ltd is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

  • Lupin Somerset Manufacturing Plant Receives EIR from USFDA

    Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

  • Pharma companies to share data on antimicrobial resistance

    The initiative launched last month (21 June) by Vivli, a non-profit clinical research data sharing organisation, will enable scientists from all over the world to access data on epidemiological, physical and genetic characteristics of organisms and their resistance to various antibiotics.

Subscribe to Industry News